MedPath

DR KUNDAN SINGH CHUFAL

🇮🇳India
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:1
Completed:0

Trial Phases

0 Phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Response Prediction to Neoadjuvant Chemoradiation in Esophageal Cancer Using Artificial Intelligence & Machine Learning

Active, not recruiting
Conditions
Esophageal Neoplasm
Interventions
Radiation: Neo-Adjuvant Radiotherapy
Drug: Neo-Adjuvant Chemotherapy
Procedure: Esophagectomy
First Posted Date
2020-07-28
Last Posted Date
2022-12-28
Lead Sponsor
Dr Kundan Singh Chufal
Target Recruit Count
150
Registration Number
NCT04489368
Locations
🇦🇺

Illawarra Cancer Care Centre, Wollongong, Australia

🇮🇳

Rajiv Gandhi Cancer Institute & Research Center, New Delhi, Delhi, India

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.